TiumBio is working on various pipelines, including an anticancer drug inhibiting both TGF-β and VEGFR-2, an endometriosis drug, and hemophilia treatment.
The market’s expectation for TiumBio is increasing because global trials of the company’s experimental drugs are expected to progress swiftly.
Monday, industry officials said that TiumBio is expected to finish patient recruitment for a global phase 2a trial of endometriosis treatment candidate TU2670 in five European countries by the end of 2022.
Considering that it usually takes two to three months to derive study results, the company will be able to derive the results by the first half of 2023, they said.
“When it comes to global trials, trial institutions do not share analysis results immediately, as in local clinical trials,” an official at TiumBio said. “Considering this, we will be able to get the results in the first half of 2023. We also hope to specify a licensing-out deal around that time.”
Also, TiumBio is in talks with several multinational pharmaceutical companies to get sponsorship for a trial of combination therapy that includes TU2218, a dual inhibitor against TGF-β and VEGFR-2. The company obtained the FDA approval for a phase 1/2 trial of TU2218 in August.
“We will be able to close the sponsorship agreement by early next year,” the TiumBio official said.
TiumBio is expected to release the results of a pre-clinical trial of TU2218 at the annual meeting of the American Association for Cancer Research (AACR) in April 2022.
“We confirmed that TU2218 inhibited the growth of cancer cells in several types of cancer including colorectal cancer, which has a meager response to a PD-1 inhibitor, in a pre-clinical trial,” the TiumBio official said. “We also confirmed excellent synergy when TU2218 was administered in combination with a PD-1 inhibitor.”
TiumBio also plans to begin a global phase 1 trial of TU7710, a hemophilia treatment, late this year or early next year.
The company said last month that it was in the final stage of producing clinical samples.
Heo Hye-min, an analyst at Kiwoom Securities, said TiumBio will have many momentums to raise its corporate value from late 2022 to 2023.
“Clinical trials of pipelines are progressing smoothly, and the company is expanding investment mainly in synergetic businesses, accumulating corporate value,” Heo said in a report. “The company will be able to stand out in 2023.”
Shares of TiumBio traded at 18,450 won ($15.55) at noon on Monday.